Olema Pharmaceuticals (OLMA) Other Non Operating Income (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Other Non Operating Income of $121000.0 for Q1 2026, up 402.5% year-over-year from $24079.6 in Q1 2025, and up 830.77% quarter-over-quarter from $13000.0 in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Other Non Operating Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Other Non Operating Income for 7 consecutive years, with $121000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 402.5% year-over-year to $121000.0; the TTM figure through Mar 2026 stood at $184000.0 (up 308.89% YoY), while the FY2025 annual figure was $23000.0, down 77.45% from the prior year.
- Other Non Operating Income climbed to $121000.0 in Q1 2026 per OLMA's latest filing, from $13000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $138000.0 in Q3 2024 and bottomed at -$120000.0 in Q3 2022.
- Historically, Other Non Operating Income has averaged $11764.7 across 5 years, with a median of $13000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 2100.0% — and 2025, when it sank 335.29%.
- Olema Pharmaceuticals' Other Non Operating Income stood at $67000.0 in 2022, then surged by 38.81% to $93000.0 in 2023, then slumped by 200.0% to -$93000.0 in 2024, then soared by 113.98% to $13000.0 in 2025, then soared by 830.77% to $121000.0 in 2026.
- Business Quant data shows OLMA's Other Non Operating Income at $121000.0 in Q1 2026, $13000.0 in Q4 2025, and $12000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -528,000.00 |
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | -40,000.00 |
| Dec 31, 2024 | -93,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 93,000.00 |
| Sep 30, 2023 | -79,000.00 |
| Jun 30, 2023 | -44,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 67,000.00 |
| Sep 30, 2022 | -120,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | -56,000.00 |